****

**TABLE OF CONTENTS**

[1. REPORT OVERVIEW 17](#_Toc144292103)

[1.1 Statement of the Report 17](#_Toc144292104)

[1.2 Executive Summary 19](#_Toc144292105)

[2. INTRODUCTION 21](#_Toc144292106)

[3. CURRENT STATUS OF IPSC INDUSTRY 22](#_Toc144292107)

[3.1 Progress Made in Autologous Cell Therapy using iPSCs 22](#_Toc144292108)

[3.1.1 Examples of Autologous iPSC-derived Cell Therapies in Development 23](#_Toc144292109)

[3.2 Manufacturing Timeline for Autologous iPSC-Derived Cell Products 24](#_Toc144292110)

[3.3 Cost of iPSC Production 25](#_Toc144292111)

[3.4 Automation in iPSC Production 26](#_Toc144292112)

[3.5 Allogeneic iPSCs Gaining Momentum 27](#_Toc144292113)

[3.5.1 Ongoing Clinical Trials involving Allogeneic iPSCs 28](#_Toc144292114)

[3.6 Share of iPSC-based Research within the Overall Stem Cell Industry 28](#_Toc144292115)

[3.7 Major Focus Areas of iPSC Companies 29](#_Toc144292116)

[3.8 Commercially Available iPSC-derived Cell Types 30](#_Toc144292117)

[3.9 Relative use of iPSC-derived Cell Types in Toxicology Testing Assays 31](#_Toc144292118)

[3.10 Currently Available iPSC Technologies 32](#_Toc144292119)

[3.10.1 Brief Descriptions of some recently introduced iPSC-related Technologies 34](#_Toc144292120)

[3.10.1.1 Nucleofector Technology 34](#_Toc144292121)

[3.10.1.2 opti-ox Technology 35](#_Toc144292122)

[3.10.1.3 MOGRIFY Technology 35](#_Toc144292123)

[3.10.1.4 Transcription Factor-Based iPSC Differentiation Technology 36](#_Toc144292124)

[3.10.1.5 Flowfect Technology 36](#_Toc144292125)

[3.10.1.6 Technology for Mass Production of Platelets from Megakaryocytes 36](#_Toc144292126)

[3.10.1.7 SynFire Technology 38](#_Toc144292127)

[4. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 39](#_Toc144292128)

[4.1 First iPSC Generation from Mouse Fibroblasts, 2006 40](#_Toc144292129)

[4.2 First Human iPSC Generation, 2007 40](#_Toc144292130)

[4.3 Creation of CiRA, 2010 40](#_Toc144292131)

[4.4 First High-Throughput Screening using iPSCs, 2012 40](#_Toc144292132)

[4.5 First iPSC Clinical Trial Approved in Japan, 2013 41](#_Toc144292133)

[4.6 First iPSC-RPE Cell Sheet Transplantation for AMD, 2014 41](#_Toc144292134)

[4.7 EBiSC Founded, 2014 41](#_Toc144292135)

[4.8 First Clinical Trial using Allogeneic iPSCs for AMD, 2017 41](#_Toc144292136)

[4.9 Clinical Trial for Parkinson’s disease using Allogeneic iPSCs, 2018 42](#_Toc144292137)

[4.10 Commercial iPSC Plant SMaRT Established, 2018 42](#_Toc144292138)

[4.11 First iPSC Therapy Center in Japan, 2019 42](#_Toc144292139)

[4.12 First U.S.-based NIH-Sponsored Clinical Trial using iPSCs, 2019 42](#_Toc144292140)

[4.13 Cynata Therapeutics’ World’s Largest Phase III Clinical Trial, 2020 43](#_Toc144292141)

[4.14 Tools and Know-how to Manufacture iPSCs in Clinical Trials, 2021 43](#_Toc144292142)

[4.15 Production of In-House iPSCs using Peripheral Blood Cells, 2022 43](#_Toc144292143)

[5. RESEARCH PUBLICATIONS ON IPSCS 44](#_Toc144292144)

[5.1 Rapid Growth in iPSC Publications 44](#_Toc144292145)

[5.1.1 PubMed Publications on Pathophysiological Research 46](#_Toc144292146)

[5.1.2 PubMed Papers in Reprogramming 46](#_Toc144292147)

[5.1.3 PubMed Papers in iPSC Differentiation 47](#_Toc144292148)

[5.1.4 PubMed Papers on the use of iPSCs in Drug Discovery 48](#_Toc144292149)

[5.1.5 PubMed Papers on iPSC-based Cell Therapy 49](#_Toc144292150)

[5.2 Percent Share of Published Articles by Disease Type 50](#_Toc144292151)

[5.3 Percent Share of Articles by Country 51](#_Toc144292152)

[6. IPSC: PATENT LANDSCAPE ANALYSIS 53](#_Toc144292153)

[6.1 Legal Status of iPSC Patents 53](#_Toc144292154)

[6.2 Patents by Jurisdiction 54](#_Toc144292155)

[6.3 iPSC Patent Applications over Time 55](#_Toc144292156)

[6.4 Global iPSC Patent Applicants as of April 19, 2023 55](#_Toc144292157)

[6.5 Inventors of iPSC Patents 58](#_Toc144292158)

[6.6 iPSC Patent Owners 61](#_Toc144292159)

[7. IPSC: CLINICAL TRIAL LANDSCAPE 65](#_Toc144292160)

[7.1 Literature and Database Search 65](#_Toc144292161)

[7.2 Number of iPSC Clinical Trials by Year 66](#_Toc144292162)

[7.3 IPSC Study Designs 66](#_Toc144292163)

[7.3.1 Therapeutic and Non-Therapeutic Studies 67](#_Toc144292164)

[7.3.2 Non-Therapeutic Clinical Trials by Use 68](#_Toc144292165)

[7.3.2.1 Top Ten Countries with the Ongoing Non-Therapeutic Studies 68](#_Toc144292166)

[7.3.2.2 Diseases Targeted by Non-Therapeutic Studies 69](#_Toc144292167)

[7.3.3 Therapeutic Studies 70](#_Toc144292168)

[7.3.3.1 Therapeutic Studies by Phase of Study 71](#_Toc144292169)

[7.3.3.2 Therapeutic Studies by Disease Type 71](#_Toc144292170)

[7.3.3.3 Examples of Therapeutic Interventional Studies 72](#_Toc144292171)

[7.3.3.4 Future Outlook for Therapeutic Clinical Trials using iPSCs 74](#_Toc144292172)

[7.4 iPSC-Based Clinical Trials with Commercialization Potential 75](#_Toc144292173)

[8. RESEARCH FUNDING FOR iPSCS 77](#_Toc144292174)

[8.1 Value of NIH Funding for iPSC Research 78](#_Toc144292175)

[8.2 Partial List of NIH Funded iPSC Research Projects 79](#_Toc144292176)

[9. M&A, COLLABORATIONS & FUNDING ACTIVITIES IN iPSC SECTOR 80](#_Toc144292177)

[9.1 Mergers and Acquisitions (M&A) in iPSC Sector 80](#_Toc144292178)

[9.1.1 Evotec & Rigenerand 80](#_Toc144292179)

[9.1.2 Catalent & RheinCell Therapeutics 81](#_Toc144292180)

[9.1.3 Axol Bioscience & Censo Biotechnologies 81](#_Toc144292181)

[9.1.4 Bayer AG & BlueRock 81](#_Toc144292182)

[9.1.5 Pluriomics & Axiogenesis 81](#_Toc144292183)

[9.2 Partnership/Collaboration/Licensing Deals in iPSC Sector 82](#_Toc144292184)

[9.2.1 Evotec & Sernova 83](#_Toc144292185)

[9.2.2 Evotec SE & Almirall, SA 84](#_Toc144292186)

[9.2.3 Quell Therapeutics & Cellistic 84](#_Toc144292187)

[9.2.3.1 Terms of the Collaboration 84](#_Toc144292188)

[9.2.4 MDimmune & YiPSCELL 85](#_Toc144292189)

[9.2.5 EdiGene & Neukio Biotherapeutics 85](#_Toc144292190)

[9.2.6 Matricelf & Ramot 85](#_Toc144292191)

[9.2.7 Evotec & Boehringer Ingelheim 85](#_Toc144292192)

[9.2.8 Plurityx, Pancella & Implant Therapeutics 86](#_Toc144292193)

[9.2.9 Century Therapeutics & Bristol Myers Squibb 86](#_Toc144292194)

[9.2.10 Terms of the Collaboration 86](#_Toc144292195)

[9.2.11 Fujifilm Cellular Dynamics & Pheno Vista Biosciences 87](#_Toc144292196)

[9.2.12 Metrion Biosciences & Bioqube Ventures 87](#_Toc144292197)

[9.2.13 Cytovia Therapeutics & Cellectis 87](#_Toc144292198)

[9.2.14 Exacis Biotherapeutics & CCRM 88](#_Toc144292199)

[9.2.15 Cynata Therapeutics & Fujifilm Corporation 88](#_Toc144292200)

[9.2.16 Bone Therapeutics & Implant Therapeutics 88](#_Toc144292201)

[9.2.17 REPROCELL & TEXCELL 89](#_Toc144292202)

[9.2.18 Jacobio & Herbecell 89](#_Toc144292203)

[9.2.19 NeuCyte & KIF1A.ORG 89](#_Toc144292204)

[9.2.20 Kite & Shoreline Biosciences 90](#_Toc144292205)

[9.2.21 Neurophth Therapeutics & Hopstem Biotechnology 90](#_Toc144292206)

[9.2.22 Allele Biotech & Cellatoz 91](#_Toc144292207)

[9.2.23 BlueRock Therapeutics, Fujifilm Cellular Dynamics & Opsis Therapeutics 91](#_Toc144292208)

[9.2.24 Newcells & Takeda 92](#_Toc144292209)

[9.2.25 Biocentriq & Kytopen 92](#_Toc144292210)

[9.2.26 Fujifilm Cellular Dynamics & Sana Biotechnology 92](#_Toc144292211)

[9.2.27 Evotec & Medical Center Hamburg-Eppendorf (UKE) 92](#_Toc144292212)

[9.2.28 NeuCyte & Seaver Autism Center for Research and Treatment 93](#_Toc144292213)

[9.2.29 Cytovia Therapeutics & National Cancer Institute 93](#_Toc144292214)

[9.2.30 Mogrify & MRC Laboratory of Molecular Biology 93](#_Toc144292215)

[9.3 Venture Capital Funding and IPOs 94](#_Toc144292216)

[9.3.1 Aspen Neuroscience 95](#_Toc144292217)

[9.3.2 Axol Biosciences Ltd. 95](#_Toc144292218)

[9.3.3 Thyas Co. Ltd. 96](#_Toc144292219)

[9.3.4 Synthego 96](#_Toc144292220)

[9.3.5 Cellino Biotech, Inc. 97](#_Toc144292221)

[9.3.6 Curi Bio 97](#_Toc144292222)

[9.3.7 Ncardia 97](#_Toc144292223)

[9.3.8 Evotec SE 98](#_Toc144292224)

[9.3.9 bit.bio 98](#_Toc144292225)

[9.3.10 Clade Therapeutics 98](#_Toc144292226)

[9.3.11 Shoreline Biosciences 98](#_Toc144292227)

[9.3.12 Kytopen 99](#_Toc144292228)

[9.3.13 Cytovia Therapeutics & CytoLynx 99](#_Toc144292229)

[9.3.14 TreeFrog Therapeutics 100](#_Toc144292230)

[9.3.15 HebeCell Corporation 100](#_Toc144292231)

[9.3.16 Neukio Biotherapeutics 100](#_Toc144292232)

[9.3.17 Stemson Therapeutics 101](#_Toc144292233)

[9.3.18 Vita Therapeutics 101](#_Toc144292234)

[9.3.19 Century Therapeutics 102](#_Toc144292235)

[9.3.20 Heartseed 102](#_Toc144292236)

[9.3.21 Mogrify 102](#_Toc144292237)

[9.3.22 Metrion Biosciences 103](#_Toc144292238)

[9.3.23 Axol Biosciences 103](#_Toc144292239)

[9.3.24 Axol Bioscience 103](#_Toc144292240)

[9.3.25 Elevate Bio 104](#_Toc144292241)

[9.3.26 Vita Therapeutics 104](#_Toc144292242)

[10. GENERATION OF INDUCED PLURIPOTENT STEM CELLS: AN OVERVIEW 105](#_Toc144292243)

[10.1 Reprogramming Factors 106](#_Toc144292244)

[10.1.1 Pluripotency-Associated Transcription Factors and their Functions 107](#_Toc144292245)

[10.1.2 Different Combinations of Factors for Different Cell Sources 109](#_Toc144292246)

[10.1.3 Delivery of Reprogramming Factors 109](#_Toc144292247)

[10.2 Integrating iPSC Delivery Methods 110](#_Toc144292248)

[10.2.1 Retroviral Vectors 111](#_Toc144292249)

[10.2.2 Lentiviral Vectors 111](#_Toc144292250)

[10.2.3 piggyBac (PB) Transposon 112](#_Toc144292251)

[10.3 Non-Integrative Delivery Systems 113](#_Toc144292252)

[10.3.1 Adenoviral Vectors 113](#_Toc144292253)

[10.3.2 Sendai Viral Vectors 114](#_Toc144292254)

[10.3.3 Plasmid Vectors 114](#_Toc144292255)

[10.3.4 Minicircles 114](#_Toc144292256)

[10.3.5 oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1) based Episomes 114](#_Toc144292257)

[10.3.6 RNA 115](#_Toc144292258)

[10.3.7 Proteins 116](#_Toc144292259)

[10.4 Comparison of Delivery Methods for generating iPSCs 116](#_Toc144292260)

[10.5 Genome Editing Technologies in iPSC Generation 118](#_Toc144292261)

[10.5.1 CRISPR/Cas9 118](#_Toc144292262)

[11. HUMAN IPSC BANKING 121](#_Toc144292263)

[11.1 Cell Sources for iPSC Banking 122](#_Toc144292264)

[11.2 Reprogramming Methods used in IPSC Banking 122](#_Toc144292265)

[11.3 Factors used in Reprogramming in Different Banks 122](#_Toc144292266)

[11.4 Workflow in iPSC Banks 123](#_Toc144292267)

[11.5 Existing iPSC Banks 124](#_Toc144292268)

[11.5.1 California Institute for Regenerative Medicine (CIRM) 124](#_Toc144292269)

[11.5.1.1 CIRM iPSC Repository 125](#_Toc144292270)

[11.5.1.2 Key Partnerships Supporting CIRM’s iPSC Repository 126](#_Toc144292271)

[11.6 Regenerative Medicine Program (RMP) 126](#_Toc144292272)

[11.6.1 Research Grade iPSC Lines for Orphan & Rare Diseases with RMP 127](#_Toc144292273)

[11.6.2 RMP’s Stem Cell Translation Laboratory (SCTL) 129](#_Toc144292274)

[11.7 Center for iPS Cell Research and Application (CiRA) 129](#_Toc144292275)

[11.8 FiT – Facility for iPS Cell Therapy 130](#_Toc144292276)

[11.9 European Bank for Induced Pluripotent Stem Cells (EBiSC) 130](#_Toc144292277)

[11.10 Korean Society for Cell Biology (KSCB) 131](#_Toc144292278)

[11.11 Human Induced Pluripotent Stem Cell Initiative (HipSci) 131](#_Toc144292279)

[11.12 RIKEN – BioResource Research Center (BRC) 131](#_Toc144292280)

[11.13 Taiwan Human Disease iPSC Consortium 133](#_Toc144292281)

[11.14 WiCell 134](#_Toc144292282)

[12. BIOMEDICAL APPLICATIONS OF IPSCS 135](#_Toc144292283)

[12.1 iPSCs in Basic Research 136](#_Toc144292284)

[12.1.1 To Understand Cell Fate Control 136](#_Toc144292285)

[12.1.2 To Understand Cell Rejuvenation 136](#_Toc144292286)

[12.1.3 To Understand Pluripotency 136](#_Toc144292287)

[12.1.4 To Study Tissue & Organ Development 137](#_Toc144292288)

[12.1.5 To Produce Human Gametes from iPSCs 137](#_Toc144292289)

[12.1.6 Providers of iPSC-Related Services for Researchers 137](#_Toc144292290)

[12.2 iPSCs in Drug Discovery 139](#_Toc144292291)

[12.2.1 Advantages 139](#_Toc144292292)

[12.2.2 Drug Discovery for Cardiovascular Diseases using iPSCs 140](#_Toc144292293)

[12.2.3 Drug Discovery for Neurological Diseases using iPSCs 142](#_Toc144292294)

[12.2.4 Drug Discovery for Rare Diseases using iPSCs 144](#_Toc144292295)

[12.3 iPSCs in Toxicology Studies 146](#_Toc144292297)

[12.3.1 Testing Drugs for DILI 147](#_Toc144292298)

[12.3.2 Examples of Drugs Tested in iPSC-derived Cells 147](#_Toc144292299)

[12.3.3 Relative use of IPSC-derived Cell Types in Toxicity Testing Studies 149](#_Toc144292300)

[12.4 iPSCs in Disease Modeling 150](#_Toc144292301)

[12.4.1 Cardiovascular Diseases Modeled with iPSC-derived Cells 155](#_Toc144292302)

[12.4.1.1 Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling 156](#_Toc144292303)

[12.4.2 Modeling Liver Diseases using iPSC-derived Hepatocytes 157](#_Toc144292304)

[12.4.3 iPSCs in Neurodegenerative Disease Modeling 159](#_Toc144292305)

[12.4.4 iPSC-derived Organoids for Modeling and Diseases 164](#_Toc144292306)

[12.4.5 Cancer-Derived iPSCs 165](#_Toc144292307)

[12.5 iPSCs in Cell-Based Therapies 166](#_Toc144292308)

[12.5.1 Companies Focusing only on iPSC-based Cell Therapy 167](#_Toc144292309)

[12.6 Other Novel Applications of iPSCs 167](#_Toc144292310)

[12.6.1 iPSCs in Tissue Engineering 168](#_Toc144292311)

[12.6.1.1 3D Bioprinting Techniques 168](#_Toc144292312)

[12.6.1.2 Biomaterials 168](#_Toc144292313)

[12.6.1.3 3D Bioprinting Strategies 168](#_Toc144292314)

[2.6.1.4 Bioprinting iPSC-derived Cells 171](#_Toc144292315)

[12.6.2 iPSCs from Farm Animals 172](#_Toc144292316)

[12.6.2.1 Porcine iPSCs 172](#_Toc144292317)

[12.6.2.2 Bovine iPSCs 172](#_Toc144292318)

[12.6.2.3 Ovine and Caprine iPSCs 172](#_Toc144292319)

[12.6.2.4 Equine iPSCs 173](#_Toc144292320)

[12.6.2.5 Avian iPSCs 173](#_Toc144292321)

[12.7 iPSCs in Animal Conservation 173](#_Toc144292322)

[12.7.1 iPSC Lines for the Preservation of Endangered Species of Animals 173](#_Toc144292323)

[12.7.2 iPSCs in Wildlife Conservation 175](#_Toc144292324)

[12.7.3 iPSCs in Cultured Meat 176](#_Toc144292325)

[13. MARKET OVERVIEW 178](#_Toc144292326)

[13.1 Global Market for iPSCs by Geography 180](#_Toc144292327)

[13.2 Global Market for iPSCs by Technology 181](#_Toc144292328)

[13.3 Global Market for iPSCs by Biomedical Application 183](#_Toc144292329)

[13.4 Global Market for iPSCs by Derived Cell Type 185](#_Toc144292330)

[13.5 Market Drivers 187](#_Toc144292331)

[13.5.1 Current Drivers Impacting the iPSC marketplace 187](#_Toc144292332)

[13.6 Market Restraints 188](#_Toc144292333)

[13.6.1 Economic Issues 188](#_Toc144292334)

[13.6.2 Genomic Instability 188](#_Toc144292335)

[13.6.3 Immunogenicity 188](#_Toc144292336)

[13.6.4 Biobanking 189](#_Toc144292337)

[14. COMPANY PROFILES 190](#_Toc144292338)

[14.1 Accellta 190](#_Toc144292339)

[14.1.1 Technology 190](#_Toc144292340)

[14.1.2 Maxells 190](#_Toc144292341)

[14.1.3 Singles 191](#_Toc144292342)

[14.1.4 Differentiation 191](#_Toc144292343)

[14.1.5 Services 191](#_Toc144292344)

[14.2 AddGene, Inc. 192](#_Toc144292345)

[14.2.1 Viral Plasmids 192](#_Toc144292346)

[14.3 Allele Biotechnology, Inc. 193](#_Toc144292347)

[14.3.1 iPSC Reprogramming and Differentiation 193](#_Toc144292348)

[14.3.2 cGMP Facility 193](#_Toc144292349)

[14.4 ALSTEM, Inc. 194](#_Toc144292350)

[14.4.1 Services 194](#_Toc144292351)

[14.4.2 iPSC-related Products 194](#_Toc144292352)

[14.4.3 Human iPS Cell Lines 195](#_Toc144292353)

[14.4.4 Inducible iPS Cell Lines 195](#_Toc144292354)

[14.4.5 Isogenic iPS Cell Lines 195](#_Toc144292355)

[14.4.6 Knockout Cell Lines 196](#_Toc144292356)

[14.5 Altos Labs 196](#_Toc144292357)

[14.6 AMS Biotechnology Ltd. (AMSBIO) 197](#_Toc144292358)

[14.6.1 iPSC-derived Cells and Differentiation Kits 197](#_Toc144292359)

[14.6.2 iPSC-derived Excitatory Neurons 197](#_Toc144292360)

[14.6.3 iPSC-derived Dopaminergic Neurons 198](#_Toc144292361)

[14.6.4 iPSC-derived GABAergic Neurons 198](#_Toc144292362)

[14.6.5 iPSC-derived Cholinergic Neurons 198](#_Toc144292363)

[14.6.6 iPSC-derived Skeletal Muscle 198](#_Toc144292364)

[14.7 Aspen Neuroscience, Inc. 199](#_Toc144292365)

[14.7.1 Aspen’s Clinical Pipeline 199](#_Toc144292366)

[14.8 Astellas Pharma, Inc. 200](#_Toc144292367)

[14.8.1 Leading Program 200](#_Toc144292368)

[14.9 Avery Therapeutics 201](#_Toc144292369)

[14.9.1 MyCardia 201](#_Toc144292370)

[14.10 Axol Bioscience Ltd. 202](#_Toc144292371)

[14.10.1 iPSC-derived Cells 202](#_Toc144292372)

[14.10.2 Disease Models 202](#_Toc144292373)

[14.10.3 Services 203](#_Toc144292374)

[14.10.4 Custom Cell Services 203](#_Toc144292375)

[14.10.5 Stem Cell Reprogramming 203](#_Toc144292376)

[14.10.6 Genome Editing 203](#_Toc144292377)

[14.10.7 Stem Cell Differentiation 204](#_Toc144292378)

[14.11 Bit.bio 205](#_Toc144292379)

[14.11.1 Opti-OX Reprogramming Technology 205](#_Toc144292380)

[14.11.2 ioCells 205](#_Toc144292381)

[14.11.3 ioWild Type Cells 206](#_Toc144292382)

[14.11.4 ioGlutamatergic Neurons 206](#_Toc144292383)

[14.11.5 ioSkeletal Myocytes 206](#_Toc144292384)

[14.11.6 ioGABAergic Neurons 206](#_Toc144292385)

[14.11.7 ioDisease Models 207](#_Toc144292386)

[14.11.8 ioGlutamatergic Neurons HTT50CAGWT 207](#_Toc144292387)

[14.12 BlueRock Therapeutics 208](#_Toc144292388)

[14.12.1 CELL + GENE Platform 208](#_Toc144292389)

[14.13 BrainXell 209](#_Toc144292390)

[14.13.1 Products 209](#_Toc144292391)

[14.13.1.1 Spinal Motor Neurons 209](#_Toc144292392)

[14.13.1.2 Midbrain Dopaminergic Neurons 210](#_Toc144292393)

[14.13.1.3 Cortical Glutamatergic Neurons 210](#_Toc144292394)

[14.13.1.4 Mixed Cortical Neurons 210](#_Toc144292395)

[14.13.1.5 Cortical Astrocytes 210](#_Toc144292396)

[14.13.1.6 Layer V Glutamatergic Neurons 210](#_Toc144292397)

[14.13.1.7 Cortical GABAergic Neurons 211](#_Toc144292398)

[14.13.1.8 Microglia 211](#_Toc144292399)

[14.13.1.9 Medium Spiny Neurons 211](#_Toc144292400)

[14.13.1.10 Spinal Astrocytes 211](#_Toc144292401)

[14.14 Brooklyn Immuno Therapeutics 212](#_Toc144292402)

[14.14.1 Synthetic mRNA 212](#_Toc144292403)

[14.14.2 Non-Viral Nucleic Acid Delivery 212](#_Toc144292404)

[14.14.3 Cellular Reprogramming 213](#_Toc144292405)

[14.14.4 Gene Editing 213](#_Toc144292406)

[14.15 Catalent Biologics 214](#_Toc144292407)

[14.15.1 Human iPSCs 214](#_Toc144292408)

[14.16 Celogics, Inc. 215](#_Toc144292409)

[14.16.1 Celo.Cardiomyocytes 215](#_Toc144292410)

[14.17 Cellaria 215](#_Toc144292411)

[14.17.1 Lung Cancer Cell Models 216](#_Toc144292412)

[14.17.2 Breast Cancer Cell Models 216](#_Toc144292413)

[14.17.3 Colon Cancer Cell Lines 216](#_Toc144292414)

[14.17.4 Ovarian Cancer Cell Lines 216](#_Toc144292415)

[14.17.5 Pancreatic Cancer Cell Lines 216](#_Toc144292416)

[14.17.6 Cancer Research Custom Services 217](#_Toc144292417)

[14.17.7 Stem Cell Services 217](#_Toc144292418)

[14.18 CellGenix, GmbH 218](#_Toc144292419)

[14.18.1 Products 218](#_Toc144292420)

[14.19 Cellino Biotech 219](#_Toc144292421)

[14.19.1 Cellino’s Technology Platform 219](#_Toc144292422)

[14.20 Cellular Engineering Technologies (CET) 220](#_Toc144292423)

[14.20.1 Products 220](#_Toc144292424)

[14.20.2 iPS Cell Lines 220](#_Toc144292425)

[14.20.3 Drug Discovery Services 221](#_Toc144292426)

[14.20.4 iPSC Reprogramming Services 221](#_Toc144292427)

[14.21 Censo Biotechnologies, Ltd. 222](#_Toc144292428)

[14.21.1 Neuroinflammation 222](#_Toc144292429)

[14.21.2 Inflammation 222](#_Toc144292430)

[14.21.3 Neurobiology 223](#_Toc144292431)

[14.22 Century Therapeutics, Inc. 223](#_Toc144292432)

[14.22.1 Cell Therapy Platform 223](#_Toc144292433)

[14.22.2 Century’s Pipeline 224](#_Toc144292434)

[14.23 Citius Pharmaceuticals, Inc. 225](#_Toc144292435)

[14.23.1 Stem Cell Platform of iMSCs 225](#_Toc144292436)

[14.24 Clade Therapeutics 226](#_Toc144292437)

[14.25 Creative Bioarray 226](#_Toc144292438)

[14.25.1 iPSC Reprogramming Kits 226](#_Toc144292439)

[14.25.2 QualiStem Episomal iPSC Reprogramming Kit 227](#_Toc144292440)

[14.25.3 QualiStem RNA iPSC Reprogramming Kit 227](#_Toc144292441)

[14.25.4 QualiStem Retrovirus iPSC Reprogramming Kit 227](#_Toc144292442)

[14.25.5 QualiStem Lentivirus iPSC Reprogramming Kit 228](#_Toc144292443)

[14.25.6 QualiStem iPSC Protein Reprogramming Kit 228](#_Toc144292444)

[14.25.7 iPSC Characterization Kits 228](#_Toc144292445)

[14.25.8 Alkaline Phosphatase Staining Assay 228](#_Toc144292446)

[14.25.9 Pluripotency Markers (Protein) 228](#_Toc144292447)

[14.25.10 Pluripotency Markers (mRNA) 229](#_Toc144292448)

[14.25.11 iPSC Differentiation Kits 229](#_Toc144292449)

[14.25.12 QualiStem iPS Cell Cardiomyocyte Differentiation Kit 229](#_Toc144292450)

[14.25.13 QualiStem Human iPS Cell Dopaminergic Neuron Differentiation Kit 229](#_Toc144292451)

[14.25.14 QualiStem iPS Cell Neural Progenitor Differentiation Kit 229](#_Toc144292452)

[14.25.15 QualiStem iPS Cell Endoderm Differentiation Kit 230](#_Toc144292453)

[14.25.16 QualiStem iPS Cell Ectoderm Differentiation Kit 230](#_Toc144292454)

[14.25.17 QualiStem iPS Cell Mesoderm Differentiation Kit 230](#_Toc144292455)

[14.25.18 QualiStem iPS Cell Hepatocyte Differentiation Kit 230](#_Toc144292456)

[14.25.19 iPSC Myogenic Progenitor Differentiation kit 231](#_Toc144292457)

[14.26 Curi Bio 231](#_Toc144292458)

[14.26.1 Disease Model Development 231](#_Toc144292459)

[14.26.2 Assay Development 232](#_Toc144292460)

[14.26.3 Discovery 232](#_Toc144292461)

[14.26.4 Cell Repositories 232](#_Toc144292462)

[14.27 Cynata Therapeutics Ltd. 233](#_Toc144292463)

[14.27.1 Cymerus Platform 233](#_Toc144292464)

[14.27.2 Clinical Development 233](#_Toc144292465)

[14.27.2.1 Graft vs. Host Disease 233](#_Toc144292466)

[14.27.2.2 Critical Limb Ischemia 234](#_Toc144292467)

[14.27.2.3 Osteoarthritis 234](#_Toc144292468)

[14.27.2.4 Acute Respiratory Syndrome 234](#_Toc144292469)

[14.27.2.5 Diabetic Wounds 235](#_Toc144292470)

[14.27.2.6 Preclinical Development 235](#_Toc144292471)

[14.27.2.7 Idiopathic Pulmonary Fibrosis 235](#_Toc144292472)

[14.27.2.8 Renal Transplantation 235](#_Toc144292473)

[14.27.2.9 Asthma 235](#_Toc144292474)

[14.27.2.10 Heart Attack 236](#_Toc144292475)

[14.27.2.11 Coronary Artery Disease 236](#_Toc144292476)

[14.28 Cytovia Therapeutics 237](#_Toc144292477)

[14.28.1 Technology 237](#_Toc144292478)

[14.28.2 iNK & CAR-iNK Cells 237](#_Toc144292479)

[14.28.3 Flex-NK Cell Engagers 238](#_Toc144292480)

[14.29 DefiniGEN 239](#_Toc144292481)

[14.29.1 OptiDIFF iPSC Platform 239](#_Toc144292482)

[14.29.2 Services 239](#_Toc144292483)

[14.29.2.1 Phenotypic Screening Services 239](#_Toc144292484)

[14.29.2.2 iPSC Differentiation Services 240](#_Toc144292485)

[14.29.2.3 Disease Modeling Services 240](#_Toc144292486)

[14.29.3 Products 240](#_Toc144292487)

[14.29.3.1 Hepatocyte WT 240](#_Toc144292488)

[14.29.3.2 NAFLD iPSC-Derived Hepatocytes 241](#_Toc144292489)

[14.29.3.3 GSD1a Disease Modeled Hepatocytes 241](#_Toc144292490)

[14.29.3.4 A1ATD Disease Modeled Hepatocytes 241](#_Toc144292491)

[14.29.3.5 Hepatocyte Familial Hypercholesterolemia (FH) 241](#_Toc144292492)

[14.29.3.6 Custom Model Development 242](#_Toc144292493)

[14.29.3.7 NAFLD PNPLA3 242](#_Toc144292494)

[14.29.3.8 NAFLD TM6SF2 Disease Modeled Hepatocytes 242](#_Toc144292495)

[14.29.3.9 Intestinal Organoids 242](#_Toc144292496)

[14.29.3.10 Intestinal Monolayer 243](#_Toc144292497)

[14.29.3.11 Pancreatic Beta Cells (WT) 243](#_Toc144292498)

[14.29.3.12 MODY3 Diabetes 243](#_Toc144292499)

[14.29.3.13 Neonatal Diabetes Pancreatic Cells 243](#_Toc144292500)

[14.30 Editas Medicine 244](#_Toc144292501)

[14.30.1 iPSC-Derived NK Cells 244](#_Toc144292502)

[14.31 ElevateBio 245](#_Toc144292503)

[14.31.1 Technologies 245](#_Toc144292504)

[14.32 Elixirgen Scientific, Inc. 246](#_Toc144292505)

[14.32.1 Technology 246](#_Toc144292506)

[14.32.2 Services 246](#_Toc144292507)

[14.32.3 iPSC Products 247](#_Toc144292508)

[14.32.4 Reagents 248](#_Toc144292509)

[14.33 EviaBio 248](#_Toc144292510)

[14.33.1 iPSCs Cryopreservation Solutions 248](#_Toc144292511)

[14.34 Evotec A.G. 249](#_Toc144292512)

[14.34.1 iPSCs Platform 249](#_Toc144292513)

[14.34.2 Drug Discoveries 250](#_Toc144292514)

[14.35 Exacis Biotherapeutics 251](#_Toc144292515)

[14.35.1 ExaCELLs 251](#_Toc144292516)

[14.36 Eyestem 252](#_Toc144292517)

[14.36.1 Eyecyte-RPE 252](#_Toc144292518)

[14.37 Fate Therapeutics 253](#_Toc144292519)

[14.37.1 iPSCs Platform 253](#_Toc144292520)

[14.37.2 Pipeline 254](#_Toc144292521)

[14.37.3 Collaborations 254](#_Toc144292522)

[14.37.3.1 Janssen Biotech 254](#_Toc144292523)

[14.37.3.2 ONO Pharmaceutical 255](#_Toc144292524)

[14.38 FUJIFILM Cellular Dynamics, Inc. (FCDI) 255](#_Toc144292525)

[14.38.1 Products 255](#_Toc144292526)

[14.38.2 MyCell Custom Services 257](#_Toc144292527)

[14.38.3 Disease Modeling Applications 257](#_Toc144292528)

[14.38.4 Drug Discovery Applications 258](#_Toc144292529)

[14.38.5 Applications in Toxicity Testing 259](#_Toc144292530)

[14.39 Heartseed, Inc. 260](#_Toc144292531)

[14.39.1 Technology 260](#_Toc144292532)

[14.40 HebeCell 261](#_Toc144292533)

[14.40.1 Technology 261](#_Toc144292534)

[14.41 Helios K.K. 262](#_Toc144292535)

[14.42 Hera BioLabs 263](#_Toc144292536)

[14.42.1 Services 263](#_Toc144292537)

[14.42.2 Products 263](#_Toc144292538)

[14.42.3 piggyBac Transposase/Transposon 263](#_Toc144292539)

[14.43 Hopstem Biotechnology 264](#_Toc144292540)

[14.43.1 Research & Development 264](#_Toc144292541)

[14.43.2 Product Pipeline 265](#_Toc144292542)

[14.44 Implant Therapeutics, Inc. 266](#_Toc144292543)

[14.44.1 Services 266](#_Toc144292544)

[14.45 iPS Portal, Inc 267](#_Toc144292545)

[14.45.1 Services 267](#_Toc144292546)

[14.45.1.1 Research Support and Contract Testing Services 267](#_Toc144292547)

[14.45.1.2 Development Support Services 268](#_Toc144292548)

[14.45.2 Business Support 268](#_Toc144292549)

[14.46 I Peace, Inc. 269](#_Toc144292550)

[14.46.1 Mass Production of iPSCs 269](#_Toc144292551)

[14.47 iXCells Biotechnologies 270](#_Toc144292552)

[14.47.1 Products 270](#_Toc144292553)

[14.47.2 Services 271](#_Toc144292554)

[14.47.3 iPS Cell Generation 271](#_Toc144292555)

[14.47.4 Genome Editing 271](#_Toc144292556)

[14.47.5 iPSC Differentiation 272](#_Toc144292557)

[14.48 iPSirius SAS 273](#_Toc144292558)

[14.48.1 IPVAC 1.0 273](#_Toc144292559)

[14.48.2 Key Features & Benefits of IPVAC 1.0 273](#_Toc144292561)

[14.49 Kytopen 275](#_Toc144292562)

[14.49.1 Flowfect Technology 275](#_Toc144292563)

[14.50 Lindville Bio Ltd. 276](#_Toc144292564)

[14.50.1 Services 276](#_Toc144292565)

[14.51 LizarBio Therapeutics 278](#_Toc144292566)

[14.51.1 Pipeline 278](#_Toc144292567)

[14.52 Lonza Group, Ltd. 279](#_Toc144292568)

[14.52.1 iPSC Manufacturing Expertise 279](#_Toc144292569)

[14.52.2 Nucleofector Technology 279](#_Toc144292570)

[14.53 Matricelf 280](#_Toc144292571)

[14.54 Merck/Sigma Aldrich 281](#_Toc144292572)

[14.54.2 Merck’s iPSC Products and Services 281](#_Toc144292573)

[14.55 Megakaryon Corporation 282](#_Toc144292574)

[14.55.1 Technology 282](#_Toc144292575)

[14.55.2 Research and Development Pipeline 283](#_Toc144292576)

[14.55.3 Cryopreservable Megakaryon Strain 284](#_Toc144292577)

[14.55.4 Treatable Diseases by Products from Megakaryon 284](#_Toc144292578)

[14.56 Metrion Biosciences, Ltd. 285](#_Toc144292579)

[14.56.1 Cardiac Safety Screening Services 285](#_Toc144292580)

[14.56.2 Neuroscience Assay Services 285](#_Toc144292581)

[14.56.3 Cardiac Assay Services 286](#_Toc144292582)

[14.56.4 Neuroscience Translational Assay Services 286](#_Toc144292583)

[14.56.5 Integrated Drug Discovery Service 286](#_Toc144292584)

[14.57 Mogrify 287](#_Toc144292585)

[14.57.1 MOGRIFY Platform 287](#_Toc144292586)

[14.57.2 epiMOGRIFY Platform 288](#_Toc144292587)

[14.58 Ncardia 289](#_Toc144292588)

[14.58.1 iPSC Platform 289](#_Toc144292589)

[14.58.2 Human iPSC-derived Cell Models 290](#_Toc144292590)

[14.58.3 Drug Discovery Solutions 290](#_Toc144292591)

[14.58.4 Developing iPSC-derived Cell Types 290](#_Toc144292592)

[14.58.5 Assay Development 291](#_Toc144292593)

[14.58.6 High-Throughput Screening 291](#_Toc144292594)

[14.59 NeuCyte 292](#_Toc144292595)

[14.59.1 SynFire Technology 292](#_Toc144292596)

[14.60 Neukio Biotherapeutics 293](#_Toc144292597)

[14.60.1 iPSC-CAR-NK 293](#_Toc144292598)

[14.61 Newcells Biotech, Ltd 294](#_Toc144292599)

[14.61.1 Retinal Platform 294](#_Toc144292600)

[14.61.2 Kidney Platform 294](#_Toc144292601)

[14.61.3 Lung Model 295](#_Toc144292602)

[14.62 NEXEL Co., Ltd. 295](#_Toc144292603)

[14.62.1 Cardiosight-S 295](#_Toc144292604)

[14.62.2 Hepatocyte-S 295](#_Toc144292605)

[14.62.3 Neurosight-S 296](#_Toc144292606)

[14.62.4 NeXST Cardiac Safety Service 296](#_Toc144292607)

[14.63 Orizuru Therapeutics, Inc. 297](#_Toc144292608)

[14.63.1 iCM Project 297](#_Toc144292609)

[14.63.2 iPIC Project 297](#_Toc144292610)

[14.64 Phenocell SAS 298](#_Toc144292611)

[14.64.1 Cells and Kits 298](#_Toc144292612)

[14.64.2 R&D Outsourcing Services 299](#_Toc144292613)

[14.65 Platelet BioGenesis 299](#_Toc144292614)

[14.65.1 Technology 299](#_Toc144292615)

[14.66 Pluristyx 300](#_Toc144292616)

[14.66.1 RTD and RTU Technologies 300](#_Toc144292617)

[14.66.2 Products 300](#_Toc144292618)

[14.66.3 Services 301](#_Toc144292619)

[14.67 ReNeuron 302](#_Toc144292620)

[14.67.1 Technology Platform 302](#_Toc144292621)

[14.68 REPROCELL USA, Inc. 303](#_Toc144292622)

[14.68.1 RNA Reprogramming Kit 303](#_Toc144292623)

[14.68.2 NutriStem Culture Medium for Human iPSCs and ES Cells 304](#_Toc144292624)

[14.68.3 Induced Pluripotent Stem Cells 304](#_Toc144292625)

[14.68.4 StemRNA Neuro 305](#_Toc144292626)

[14.68.5 iPSCs Master Cell Bank 305](#_Toc144292627)

[14.69 RxCell, Inc. 306](#_Toc144292628)

[14.69.1 Services 306](#_Toc144292629)

[14.70 SCG Cell Therapy Pte Ltd. 307](#_Toc144292630)

[14.70.1 Acquisition of Technology 307](#_Toc144292631)

[14.71 Shoreline Biosciences 308](#_Toc144292632)

[14.71.1 iNK Cell Platform 308](#_Toc144292633)

[14.71.2 iPSC-Derived iMACs 308](#_Toc144292634)

[14.72 Stemson Therapeutics 309](#_Toc144292635)

[14.72.1 Hair Follicle Biology 309](#_Toc144292636)

[14.73 Stemina Biomarker Discovery 310](#_Toc144292637)

[14.73.1 Cardio quickPredict 310](#_Toc144292638)

[14.73.2 devTOX quickPredict 311](#_Toc144292639)

[14.74 Synthego Corp. 311](#_Toc144292640)

[14.74.1 Knockout iPSCs 311](#_Toc144292641)

[14.74.2 Knock-in iPSCs 312](#_Toc144292642)

[14.75 Tempo Bioscience 312](#_Toc144292643)

[14.75.1 Human iPSC-derived Sensory Neurons 312](#_Toc144292644)

[14.75.2 Human iPS-derived Schwann Cells 313](#_Toc144292645)

[14.75.3 Human iPS-derived Phagocytes 313](#_Toc144292646)

[14.75.4 Human iPSC-derived CD14+ Monocytes 313](#_Toc144292647)

[14.75.5 Human iPSC-derived Cardiomyocytes 313](#_Toc144292648)

[14.75.6 Human iPSC-derived Kidney Proximal Tubules and Podocyte 3D Spheroids 314](#_Toc144292649)

[14.75.7 Human iPSC-derived Osteoblasts 314](#_Toc144292650)

[14.75.8 Human iPSC-derived MSCs 314](#_Toc144292651)

[14.75.9 Human iPSC-derived Retinal Pigment Epithelials 314](#_Toc144292652)

[14.75.10 Human iPS-derived Motor Neurons 315](#_Toc144292653)

[14.75.11 Human iPSC-derived Microglia 315](#_Toc144292654)

[14.75.12 Human iPSC-derived Keratinocytes 315](#_Toc144292655)

[14.75.13 Human iPSC-derived Melanocytes 315](#_Toc144292656)

[14.75.14 Human iPSC-derived Dopaminergic Neurons 316](#_Toc144292657)

[14.75.15 Human iPSC-derived Cortical Neurons 316](#_Toc144292658)

[14.75.16 Human iPSC-derived Oligodendrocyte Progenitor Cells (OPCs) 316](#_Toc144292659)

[14.75.17 Human iPSC-derived Astrocytes 316](#_Toc144292660)

[14.75.18 Human iPSC-derived Neural Progenitor Cells 317](#_Toc144292661)

[14.76 Thyas, Co., Ltd. 317](#_Toc144292662)

[14.76.1 iTCR-T (iPSC-derived TCR-T) 317](#_Toc144292663)

[14.76.2 iCAR-NK/ILC (iPSC-derived CAR-NK/ILC) 318](#_Toc144292664)

[14.76.3 Thya’s Product Pipeline 318](#_Toc144292665)

[14.77 Universal Cells 319](#_Toc144292666)

[14.77.1 Technology 319](#_Toc144292667)

[14.77.2 Editing the Genome without Breaking It 320](#_Toc144292668)

[14.77.3 Cells for Every Organ 320](#_Toc144292669)

[14.78 ViaCyte, Inc. 321](#_Toc144292670)

[14.78.1 PEC-01 Cells 321](#_Toc144292671)

[14.78.2 Device Engineering 321](#_Toc144292672)

[14.79 Vita Therapeutics 322](#_Toc144292673)

[14.79.1 Technology 322](#_Toc144292674)

[14.79.2 VTA-100 322](#_Toc144292675)

[14.80 XCell Science, Inc. 323](#_Toc144292676)

[14.80.1 Cell Products 323](#_Toc144292677)

[14.80.2 Control Lines 324](#_Toc144292678)

[14.80.3 Services 324](#_Toc144292679)

[14.81 Yashraj Biotechnology, Ltd. 325](#_Toc144292680)

[14.81.1 iPSC and Differentiated Derivatives 325](#_Toc144292681)

[14.81.1.1 iPSC-derived Human Cardiomyocytes 325](#_Toc144292682)

[14.81.1.2 iPSC-derived Hepatocytes 326](#_Toc144292683)

[14.81.1.3 iPSC-derived Astrocytes 326](#_Toc144292684)

[14.81.1.4 iPSC-derived Forebrain Motor Neurons 326](#_Toc144292685)

[14.81.1.5 iPSC-derived Endothelial Cells 326](#_Toc144292686)

[14.81.1.6 iPSC-derived Midbrain Dopaminergic Neurons 326](#_Toc144292687)

[14.82 YiPCELL 327](#_Toc144292688)

[14.82.1 R&D Programs 327](#_Toc144292689)

[14.82.2 MIUChon 327](#_Toc144292690)

[14.82.3 MIUKin 327](#_Toc144292691)

[14.82.4 MIURon 328](#_Toc144292692)

**INDEX OF FIGURES**

[FIGURE 3.1: Manufacturing Timeline for Autologous iPSC-derived Cell Products 24](#_Toc144292693)

[FIGURE 3.2: Manufacturing Cost for Manual and Automated Processes 25](#_Toc144292694)

[FIGURE 3.3: Technical Set-up of the StemCellFactory (SCF) 26](#_Toc144292695)

[FIGURE 3.4: Share of iPSC-based Research within the Overall Stem Cell Industry 29](#_Toc144292696)

[FIGURE 3.5: Major Focuses of iPSC Companies 30](#_Toc144292697)

[FIGURE 3.6: Commercially Available iPSC-derived Cell Types 31](#_Toc144292698)

[FIGURE 3.7: Relative use of iPSC-derived Cell Types in Toxicology Testing Assays 32](#_Toc144292699)

[FIGURE 3.8: Schematic Comparing Nucleofection and Lipofection 35](#_Toc144292700)

[FIGURE 3.9: Schematic of Steps involved in Platelet Production 37](#_Toc144292701)

[FIGURE 5.1: Number of Research Publications on iPSCs in PubMed.gov, 2006 to Present 45](#_Toc144292702)

[FIGURE 5.2: Number of Published Papers in Pathophysiological Research, 2006 to Present 46](#_Toc144292703)

[FIGURE 5.3: Number of PubMed Papers in Reprogramming, 2008 to Present 47](#_Toc144292704)

[FIGURE 5.4: Number of PubMed papers on iPSC Differentiation, 2006 to Present 48](#_Toc144292705)

[FIGURE 5.5: PubMed Papers on the use of iPSCs in Drug Discovery, 2006 to Present 49](#_Toc144292706)

[FIGURE 5.6: PubMed Papers on the use of iPSCs in Cell Therapy, 2008 to Present 50](#_Toc144292707)

[FIGURE 5.7: Percent Share of Published Articles by Disease Type 51](#_Toc144292708)

[FIGURE 5.8: Percent Share of Articles by Country 52](#_Toc144292709)

[FIGURE 6.1: Legal Status of iPSC Patents 53](#_Toc144292710)

[FIGURE 6.2: iPSC Patent Applications over Time, 2000-2022 55](#_Toc144292711)

[FIGURE 7.1: Number of iPSC Clinical Trials by Year, 2006-April 2023 66](#_Toc144292712)

[FIGURE 7.2: Study Designs in iPSC Clinical Trials 67](#_Toc144292713)

[FIGURE 7.3: Therapeutic and Non-Therapeutic Studies 67](#_Toc144292714)

[FIGURE 7.4: Non-Therapeutic Clinical Trials by Use 68](#_Toc144292715)

[FIGURE 7.5: Top Ten Countries with the Ongoing Non-Therapeutic Studies 69](#_Toc144292716)

[FIGURE 7.6: Diseases Targeted by Non-Therapeutic Studies 70](#_Toc144292717)

[FIGURE 7.7: Therapeutic Studies by Type of iPSCs Used 70](#_Toc144292718)

[FIGURE 7.8: Therapeutic Studies by Phase of Study 71](#_Toc144292719)

[FIGURE 7.9: Therapeutic Studies by Disease Type 72](#_Toc144292720)

[FIGURE 8.1: Number of NIH Funding for iPSC Projects, 2010 - May 2022 77](#_Toc144292721)

[FIGURE 8.2: Value of NIH Funding for iPSC Research, 2010-2022 78](#_Toc144292722)

[FIGURE 10.1: Overview of iPSC Technology 105](#_Toc144292723)

[FIGURE 10.2: Generation of iPSCs from MEF Cultures using 24 Factors by Yamanaka 106](#_Toc144292724)

[FIGURE 10.3: The Roles of OSKM Factors in the Induction of iPSCs 107](#_Toc144292725)

[FIGURE 10.4: Schematic of Delivery Methods for iPSC Induction 110](#_Toc144292726)

[FIGURE 10.5: Schematic of Retroviral Delivery Method 111](#_Toc144292727)

[FIGURE 10.6: Schematic of Lentiviral Delivery 112](#_Toc144292728)

[FIGURE 10.7: piggyBac (PB) Transposon Delivery 112](#_Toc144292729)

[FIGURE 10.8: Adenoviral Vector Delivery 113](#_Toc144292730)

[FIGURE 10.9: oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1) based Episomes 115](#_Toc144292731)

[FIGURE 10.10: RNA Delivery 115](#_Toc144292732)

[FIGURE 10.11: Protein Delivery 116](#_Toc144292733)

[FIGURE 11.1: Workflow in iPSC Banks 124](#_Toc144292734)

[FIGURE 12.1: Biomedical Applications of iPSCs: An Overview 135](#_Toc144292735)

[FIGURE 12.2: Basic Cell Types Differentiated from iPSCs 139](#_Toc144292736)

[FIGURE 12.3: Advantages of iPSCs in Drug Discovery 140](#_Toc144292737)

[FIGURE 12.4: iPSCs and their Potential for Toxicity Testing and Drug Screening 146](#_Toc144292738)

[FIGURE 12.5: Testing Drugs for Drug Induced Liver Injury using iPSCs 147](#_Toc144292739)

[FIGURE 12.6: Relative use of IPSC-derived Cell Types in Toxicity Testing Studies 150](#_Toc144292740)

[FIGURE 12.7: Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling 157](#_Toc144292741)

[FIGURE 12.8: Schematic of Techniques used for iPSC Bioprinting 169](#_Toc144292742)

[FIGURE 12.9: Schematic Showing the use of iPSCs in Protecting Endangered Species 175](#_Toc144292743)

[FIGURE 12.10: General Workflow for Cultured Meat Production 176](#_Toc144292744)

[FIGURE 13.1: Estimated Global Market for iPSCs by Geography, 2023-2030 180](#_Toc144292745)

[FIGURE 13.2: Estimated Global Market for iPSCs by Technology, 2023-2030 182](#_Toc144292746)

[FIGURE 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2023-2030 185](#_Toc144292747)

[FIGURE 13.4: Estimated Global Market for iPSCs by Derived Cell Type 186](#_Toc144292748)

[FIGURE 14.1: Century’s Approach in iPSC Therapy 224](#_Toc144292749)

[FIGURE 14.2: Elixirgen’s iPSCs Differentiation 247](#_Toc144292750)

[FIGURE 14.3: MyCell Custom Services 257](#_Toc144292751)

[FIGURE 14.4: Hopstem’s Research & Development 265](#_Toc144292752)

[FIGURE 14.5: Kytopen’s Push Button System 275](#_Toc144292753)

[FIGURE 14.6: Manufacturing Flow of Products from Magakaryon 283](#_Toc144292754)

[FIGURE 14.7: Treatable Diseases by Products from Megakaryon 284](#_Toc144292755)

[FIGURE 14.8: Schematic of developing iPSC Neurons by SynFire Technology 292](#_Toc144292756)

[FIGURE 14.9: Cardio quickPredict Process 310](#_Toc144292757)

[FIGURE 14.10: Schematic of Thya’s iTCR-T (iPSC-derived TCR-T) 318](#_Toc144292758)

[FIGURE 14.11: Thya’s iCAR-NK/ILC (iPSC-derived CAR-NK/ILC) 318](#_Toc144292759)

**INDEX OF TABLES**

[TABLE 3.1: Progression of Autologous iPS-derived Cell Therapies toward the Clinic 23](#_Toc144292760)

[TABLE 3.2: Examples of Autologous iPSC-derived Cell Therapies in Development 23](#_Toc144292761)

[TABLE 3.3: Examples of Clinical Trials involving Allogeneic iPSCs 28](#_Toc144292762)

[TABLE 3.4: Currently Available iPSC Technologies 34](#_Toc144292763)

[TABLE 4.1: Timeline of Important Milestones Reached in iPSC Industry, 2006 to Present 39](#_Toc144292764)

[TABLE 5.1: Number of Research Publications on iPSCs in PubMed.gov, 2006 to Present 45](#_Toc144292765)

[TABLE 6.1: Number of iPSC Patents Filed by Jurisdiction, as of April 2023 54](#_Toc144292766)

[TABLE 6.2: Global iPSC Patent Applicants, as of April 2023 56](#_Toc144292767)

[TABLE 6.2: (CONTINUED) 57](#_Toc144292768)

[TABLE 6.2: (CONTINUED) 58](#_Toc144292769)

[TABLE 6.3: Inventors of iPSC Patents, as of April 2023 59](#_Toc144292770)

[TABLE 6.3: (CONTINUED) 60](#_Toc144292771)

[TABLE 6.3: (CONTINUED) 61](#_Toc144292772)

[TABLE 6.4: Owners of iPSC Patents 62](#_Toc144292773)

[TABLE 6.4: (CONTINUED) 63](#_Toc144292774)

[TABLE 6.4: (CONTINUED) 64](#_Toc144292775)

[TABLE 7.1: Recruitment Status of iPSC Clinical Trials 65](#_Toc144292776)

[TABLE 7.2: Examples of Therapeutic Interventional Studies 72](#_Toc144292777)

[TABLE 7.2: (CONTINUED) 73](#_Toc144292778)

[TABLE 7.2: (CONTINUED) 74](#_Toc144292779)

[TABLE 8.1: A Partial List of Research Projects Supported by NIH 79](#_Toc144292780)

[TABLE 9.1: Mergers and Acquisitions (M&A) in iPSC Sector, 2017 to Present 80](#_Toc144292781)

[TABLE 9.2: Partnership/Collaboration Deals in iPSC Sector 82](#_Toc144292782)

[TABLE 9.2: (CONTINUED) 83](#_Toc144292783)

[TABLE 9.3: Venture Capital Funding and IPOs 94](#_Toc144292784)

[TABLE 10.1: Pluripotency-Associated Transcription Factors and their Functions 108](#_Toc144292785)

[TABLE 10.2: Different Combinations of Factors for Different Cell Sources 109](#_Toc144292786)

[TABLE 10.3: Comparison of Delivery Methods for in Producing iPSCs 117](#_Toc144292787)

[TABLE 10.4: iPSC Disease Models Generated by CRISPR/Cas9 119](#_Toc144292788)

[TABLE 10.4: (CONTINUED) 120](#_Toc144292789)

[TABLE 11.1: Cell Sources and Reprogramming Agents Used in iPSC Banks 123](#_Toc144292790)

[TABLE 11.2: Diseased iPSC Lines Available in CIRM Repository 125](#_Toc144292791)

[TABLE 11.3: CIRM’s iPSC Initiative Awards 126](#_Toc144292792)

[TABLE 11.4: Research Grade iPSCs Available with RMP 127](#_Toc144292793)

[TABLE 11.5: Research Grade iPSC Lines for Orphan & Rare Diseases with RMP 128](#_Toc144292794)

[TABLE 11.6: SCTL’s Collaborations 129](#_Toc144292795)

[TABLE 11.7: A Partial List of iPSC Lines Available with EBiSC 130](#_Toc144292796)

[TABLE 11.8: List of Disease-Specific iPSCs Available with RIKEN 131](#_Toc144292797)

[TABLE 11.8: (CONTINUED) 132](#_Toc144292798)

[TABLE 11.8: (CONTINUED) 133](#_Toc144292799)

[TABLE 11.9: An Overview of iPSC Banks Worldwide 134](#_Toc144292800)

[TABLE 12.1: Providers of iPSC Lines & Parts Thereof for Research 138](#_Toc144292801)

[TABLE 12.2: Drug Discovery for Cardiovascular Diseases using iPSCs 140](#_Toc144292802)

[TABLE 12.2: (CONTINUED) 141](#_Toc144292803)

[TABLE 12.2: (CONTINUED) 142](#_Toc144292804)

[TABLE 12.3: Drug Discovery for Neurological and Neuropsychiatic Diseases using iPSCs 143](#_Toc144292805)

[TABLE 12.3: (CONTINUED) 144](#_Toc144292806)

[TABLE 12.4: Drug Discovery for Rare Diseases using iPSCs 144](#_Toc144292807)

[TABLE 12.5: Examples of Drugs Tested in iPSC-derived Cells 148](#_Toc144292808)

[TABLE 12.5: (CONTINUED) 149](#_Toc144292809)

[TABLE 12.6: Published Human iPSC Models 151](#_Toc144292810)

[TABLE 12.6: (CONTINUED) 152](#_Toc144292811)

[TABLE 12.6: (CONTINUED) 153](#_Toc144292812)

[TABLE 12.6: (CONTINUED) 154](#_Toc144292813)

[TABLE 12.6: (CONTINUED) 155](#_Toc144292814)

[TABLE 12.7: Partial List of Cardiovascular & other Related Diseases Modeled using iPSCs 156](#_Toc144292815)

[TABLE 12.8: Liver Diseases and Therapeutic Interventions Modeled using iPSCs 158](#_Toc144292816)

[TABLE 12.8: (CONTINUED) 159](#_Toc144292817)

[TABLE 12.9: Examples of iPSC-based Neurodegenerative Disease Modeling 160](#_Toc144292818)

[TABLE 12.9: (CONTINUED) 161](#_Toc144292819)

[TABLE 12.9: (CONTINUED) 162](#_Toc144292820)

[TABLE12.9: (CONTINUED) 163](#_Toc144292821)

[TABLE 12.10: Organoid Types and Disease Modeling Applications 164](#_Toc144292822)

[TABLE 12.11: Examples of Cancer-derived iPSCs 165](#_Toc144292823)

[TABLE 12.12: Diseases Addressed by iPSC-derived Cells in Studies in Advanced Stages 166](#_Toc144292824)

[TABLE 12.13: Companies focusing exclusively on developing iPSC-based Therapies 167](#_Toc144292825)

[TABLE 12.14: Features of Different Bioprinting Techniques 170](#_Toc144292826)

[TABLE 12.15: Bioprinting of iPSC-derived Tissues 171](#_Toc144292827)

[TABLE 12.16: Achievements made using iPSCs for the Conservation of Animals 174](#_Toc144292828)

[TABLE 12.17: Companies using iPSCs for Cultured Meat Production 177](#_Toc144292829)

[TABLE 13.1: Estimated Global Market for iPSCs by Geography, 2023-2030 180](#_Toc144292830)

[TABLE 13.2: Estimated Global Market for iPSCs by Technology, 2023-2030 182](#_Toc144292831)

[TABLE 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2023-2030 184](#_Toc144292832)

[TABLE 13.4: Global Market for iPSCs by Derived Cell Type, 2022-2030 186](#_Toc144292833)

[TABLE 14.1: Aspen’s Clinical Pipeline 199](#_Toc144292834)

[TABLE 14.2: iPS Cell Lines from CET 221](#_Toc144292835)

[TABLE 14.3: Century Therapeutics’ Pipeline Products 224](#_Toc144292836)

[TABLE 14.4: Cytovia’s Product Pipeline 238](#_Toc144292837)

[TABLE 14.5: Fate Therapeutics’ Product Pipeline 254](#_Toc144292838)

[TABLE 14.6: HebeCell’s Product Pipeline 261](#_Toc144292839)

[TABLE 14.7: Healios’ Research and Development Status 262](#_Toc144292840)

[TABLE 14.8: Hopstem’s Product Pipeline 265](#_Toc144292841)

[TABLE 14.9: LizarBio’s Pipeline Products 278](#_Toc144292842)

[TABLE 14.10: Megakaryon’s Multiple Pipelines for iPS Platelet Products 283](#_Toc144292843)

[TABLE 14.11: StemRNA Human iPSCs from ReproCELL 304](#_Toc144292844)

[TABLE 14.12: Thya’s Product Pipeline 319](#_Toc144292845)

**About BioInformant**

BioInformant is the first and only market research firm to specialize in the stem cell industry.

BioInformant research has been cited by prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.

Serving Fortune 500 companies that include Pfizer, Goldman Sachs, and GE Healthcare, BioInformant is your global leader in stem cell industry data.